Q to Q growth in terms of number of tests has been less than expected by Street to warrant higher valuation at this point. I believe Dew pointed this out on his posts.
It's short term. With their additional collaborations with providers, the uptick for coming Q's should trend up noticeably.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.